Linagliptin,Markets and News,API,Linagliptin,668270-12-0,ANQING CHICO PHARMACEUTICAL

Abstract

Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor utilized in the management of type 2 diabetes mellitus. Developed by Boehringer Ingelheim, it offers a unique pharmacokinetic profile, including minimal renal excretion. This paper provides a comprehensive overview of linagliptin, encompassing its chemical properties, development history, approval timeline, market presence, competitive landscape, and the impact of generic formulations.

Keywords

Linagliptin, DPP-4 inhibitor, type 2 diabetes mellitus, chemical properties, market analysis, global sales, generics.

Introduction

Linagliptin, marketed under the brand names Tradjenta and Trajenta, is an oral medication prescribed for the management of type 2 diabetes mellitus. As a selective DPP-4 inhibitor, it enhances insulin secretion and inhibits glucagon release, thereby improving glycemic control. Notably, linagliptin's pharmacokinetic profile allows for once-daily dosing without the need for renal dose adjustment.

Chemical Properties

Linagliptin has the chemical formula C25H28N8O2 and a molar mass of approximately 472.54 g·mol−1. Its IUPAC name is 8-[(3R)-3-Aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione. The structural design of linagliptin contributes to its potent and selective inhibition of DPP-4, distinguishing it from other protease inhibitors.

Development and Approval Timeline

Linagliptin was developed by Boehringer Ingelheim. The compound was identified as BI-1356 during its development phase. Linagliptin received approval from the U.S. Food and Drug Administration (FDA) on May 2, 2011, for use in improving glycemic control in adults with type 2 diabetes mellitus.

Time on the Market

Since its approval in 2011, linagliptin has been available in the United States for over a decade. Its sustained presence indicates acceptance among healthcare providers and patients, particularly for those seeking a DPP-4 inhibitor with minimal renal excretion.

Global Sales and Market Competition

While specific global sales figures for linagliptin are not publicly disclosed, its market position is influenced by competition from other DPP-4 inhibitors such as sitagliptin, saxagliptin, and alogliptin. The diabetes medication market is characterized by a variety of treatment options, including both oral and injectable therapies, catering to diverse patient needs. Linagliptin's unique pharmacokinetic profile, including its minimal renal excretion, differentiates it from competitors and may influence prescribing decisions.

Generics and Related Developments

As of August 2021, linagliptin became available as a generic medication in the United States. The introduction of generic formulations has increased accessibility and reduced costs, aligning with global efforts to make diabetes treatments more affordable. Generic availability is expected to intensify market competition, potentially impacting the market share of brand-name linagliptin products.

Conclusion

Linagliptin represents a significant advancement in the pharmacological management of type 2 diabetes mellitus. Its development, characterized by strategic chemical modifications, has resulted in a medication that offers efficacy with a favorable side effect profile. The introduction of generics has further expanded its reach, underscoring the importance of such therapies in global diabetes care. As the market evolves, linagliptin's unique pharmacokinetic properties may continue to influence its position within the competitive landscape.

Active Pharmaceutical Ingredient
668270-12-0
Linagliptin, (chemical grade, purity ≥99.0%) are currently supplied by our company. [Own compliance factory, fully support factory audit] For details, you can call the bottom line to get the latest price of the product!

Disclaimer:Products are only available to countries where there is no valid patent protection. Products still covered by patents rights are available exclusively for experimental or registration purpose pursuant to national applicable law, and shall be sold in strict accordance with the laws of the People's Republic of China and the laws of the Buyer's country. All products are not for human use. Buyer is obligated for evaluation of the patent situation in its domestic market and shall be held liable for uses which do not fall within the scope of the experimental or registration use exception and are not permitted by national applicable law.

References

• Linagliptin. (n.d.). In Wikipedia. Retrieved from https://en.wikipedia.org/wiki/Linagliptin

• Linagliptin: Uses, Interactions, Mechanism of Action. (n.d.). In DrugBank Online. Retrieved from https://go.drugbank.com/drugs/DB08882

• Linagliptin - an overview. (n.d.). In ScienceDirect Topics. Retrieved from https://www.sciencedirect.com/topics/chemistry/linagliptin

• Linagliptin - PubChem. (n.d.). In PubChem. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Linagliptin

• If there is any infringement, please apologize and delete. If there are any errors, welcome to criticize and correct.
  Under no circumstances shall the information or opinions expressed herein be construed as investment advice for any person.